Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis

References

• Diehl AM, Day C, Longo DL. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063–2072.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol. 2012;9:152–161.
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–324.
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465.
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–356.
   PubMed Web of Science ®Google Scholar
• Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–425. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321–350.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–78.e5. quiz e14-5.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.
   PubMed Web of Science ®Google Scholar
• Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460–468. quiz 469.
   PubMed Web of Science ®Google Scholar
• Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–388. quiz e15-6.
   PubMed Web of Science ®Google Scholar
• Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25:2280–2289.
   PubMed Web of Science ®Google Scholar
• Stahl JM, Malhotra S. Obesity surgery indications and contraindications. In: Jonathan M. Stahl, Sandeep Malhotra, editors. Wyckoff Heights Medical Center. StatPearls. 2019 Feb 28.
   Google Scholar
• Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): review of Phase 2 and 3 Trials. J Clin Transl Hepatol. 2018;6:1–12.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. In: Sci Rep. 2016;6.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–582.e1.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal AJ, Loomba R, et al. REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019;84:105803. [Internet]..
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–690.
   PubMed Web of Science ®Google Scholar
• Struik D, Dommerholt MB, Jonker JW. Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. Curr Opin Lipidol. 2019;30:235–243.
   PubMed Web of Science ®Google Scholar
• Nies VJM, Sancar G, Liu W, et al. Fibroblast growth factor signaling in metabolic regulation. Front. Endocrinol. (Lausanne). .2016;6:193. DOI: 10.3389/fendo.2015.00193
   Web of Science ®Google Scholar
• Zhou M, Wang X, Phung V, et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014;74:3306–3316.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391:1174–1185.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2019; 1–15
   Google Scholar
• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–266.
   PubMed Web of Science ®Google Scholar
• Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol. 2016;78:223–241.
   PubMed Web of Science ®Google Scholar
• Frayling TM, Beaumont RN, Jones SE, et al. A common allele in FGF21 associated with sugar intake is associated with body shape, lower total body-fat percentage, and higher blood pressure. Cell Rep. 2018;23:327–336.
   PubMed Web of Science ®Google Scholar
• Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139:456–463.
   PubMed Web of Science ®Google Scholar
• Domouzoglou EM, Naka KK, Vlahos AP, et al. Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21. Am. J. Physiol Hear Circ Physiol. 2015;309:H1029–H1038.
   PubMed Web of Science ®Google Scholar
• Markan KR. Defining “FGF21 Resistance” during obesity: controversy, criteria and unresolved questions. F1000Res. 2018;7:289.
   PubMedGoogle Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627–1635. 2005, 115, 1627.pdf.
   PubMed Web of Science ®Google Scholar
• Jimenez V, Jambrina C, Casana E, et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med. 2018;10:e8791.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148:774–781.
   PubMed Web of Science ®Google Scholar
• Lan T, Morgan DA, Rahmouni K, et al. FGF19, FGF21, and an FGFR1/β-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab. 2017;26:709–718.e3.
   PubMed Web of Science ®Google Scholar
• Hecht R, Li YS, Sun J, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of Type 2 diabetes. PLoS ONE. 2012;7:e49345.
   Web of Science ®Google Scholar
• Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 Analog, in obese human subjects with type 2 diabetes. Cell Metab. [Internet]. 2013;18:333–340. Available from. .
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Zavons C, et al. The role of adiponectin in the pathogenesis and treatmentof non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365–383.
   PubMed Web of Science ®Google Scholar
• Talukdar S, Zhou Y, Li D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. [Internet]. 2016;23:427–440.
   PubMed Web of Science ®Google Scholar
• Kim AM, Somayaji VR, Dong JQ, et al. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes Metab. 2017;19:1762–1772.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation,successful approach to drug delivery. Drug Discov Today. 2005;10:1451–1458.
   PubMed Web of Science ®Google Scholar
• Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes. 2012;61:505–512.
   PubMed Web of Science ®Google Scholar
• Charles ED, Neuschwander-Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and Type 2 diabetes: results from a randomized Phase 2 Study. Obesity. 2019;27:41–49.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2018;392:2705–2717. [Internet].
   PubMed Web of Science ®Google Scholar
• Cho H, Daniel T, Buechler YJ, et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc Natl Acad Sci. 2011;108:9060–9065.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kurosu H, Yamamoto M, et al. betaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci. 2007;104:7432–7437.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. βklotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22:1006–1014.
   PubMed Web of Science ®Google Scholar
• Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007;27:3417–3428.
   PubMed Web of Science ®Google Scholar
• Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–152.
   PubMed Web of Science ®Google Scholar
• Krupinski J, Morgan N, Rozmen A, et al. Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2016;64:749A.
   Google Scholar
• Farrell G, Schattenberg JM, Leclercq I, et al. mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis. Hepatology. 2019;69:2241–2257.
   PubMed Web of Science ®Google Scholar
• Luo Y, Krupinski J, Gao S, et al. BMS-986036, a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and Pro-C3 in a mouse model of non-alcoholic steatohepatitis. J Hepatol. 2018;68:S396–S397. [Internet]..
   Web of Science ®Google Scholar
• Charles ED, Morrow L, Hompesch M, et al. A phase 1 study of BMS-986036 (pegylated FGF21) in healthy obese subjects. Hepatology. 2016;64:546A.
   Web of Science ®Google Scholar
• Dong JQ, Rossulek M, Somayaji VR, et al. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br J Clin Pharmacol. 2015;80:1051–1063.
   PubMed Web of Science ®Google Scholar
• Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69:1075–1086.
   PubMed Web of Science ®Google Scholar
• Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51–69.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Lin VY, Goetz R, et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008;8:77–83.
   PubMed Web of Science ®Google Scholar
• Bookout AL, De Groot MHM, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013;19:1147–1152.
   PubMed Web of Science ®Google Scholar
• Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor. Proc Natl Acad Sci. 2012;109:3143–3148.
   PubMed Web of Science ®Google Scholar
• Li X, Stanislaus S, Asuncion F, et al. FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPARα and PPARγ agonists. J Bone Miner Res. 2017;32:834–845.
   PubMed Web of Science ®Google Scholar
• Xu J, Bussiere J, Yie J, et al. Polyethylene glycol modified fgf21 engineered to maximize potency and minimize vacuole formation. Bioconjug Chem. 2013;24:915–925.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361–371.
   PubMed Web of Science ®Google Scholar
• FDA/CDER. noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for industry DRAFT GUIDANCE. Fda [Internet]. 2018; Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
   Google Scholar
• Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for non-alcohol related fattyliver disease (NAFLD). Cochrane Database Syst Rev. 2017;3:CD011640.
   PubMedGoogle Scholar
• Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264–1281.e4.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:1–15.
   PubMed Web of Science ®Google Scholar
• Zhao L, Niu J, Lin H, et al. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases. EBioMedicine. [Internet]. 2019;48:462–477.
   PubMed Web of Science ®Google Scholar